PharmaCyte Biotech (PMCB) director awarded 119,170 stock options at $0.67

Rhea-AI Filing Summary

PharmaCyte Biotech director Jonathan Schechter received a grant of stock options for 119,170 shares of Common Stock. The options have a $0.67 exercise price, expire on March 30, 2036, and were awarded as compensation, not an open-market purchase. They vest in full at the issuer's next annual stockholder meeting, subject to his continued service, leaving him with 119,170 options following this grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SCHECHTER JONATHAN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	119,170	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 119,170 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 119,170 options Exercise price: $0.67 per share Expiration date: March 30, 2036 +1 more

4 metrics

Options granted 119,170 options Grant of Stock Option (Right to Buy) on March 31, 2026

Exercise price $0.67 per share Conversion or exercise price of the stock options

Expiration date March 30, 2036 Option expiration for the Stock Option (Right to Buy)

Total options after grant 119,170 options Total derivative securities following this compensation award

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Common Stock, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

annual meeting of stockholders financial

"The options shall vest in full on the date of the Issuer's next annual meeting of stockholders"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHECHTER JONATHAN

(Last) (First) (Middle)

C/O PHARMACYTE BIOTECH, INC.

3960 HOWARD HUGHES PARKWAY, SUITE 500

(Street)

LAS VEGAS NEVADA 89169

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PharmaCyte Biotech, Inc. [ PMCB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.67	03/31/2026		A		119,170		(1)	03/30/2036	Common Stock	119,170	$0	119,170	D

Explanation of Responses:

1. The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Schechter.

	/s/ Jonathan Schechter	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PMCB director Jonathan Schechter report on this Form 4?

Jonathan Schechter reported receiving a grant of stock options for 119,170 shares of PharmaCyte Biotech Common Stock. The options were granted as compensation, not bought on the open market, and give him the right to purchase shares at a fixed exercise price in the future.

What are the key terms of Jonathan Schechter’s PMCB stock option grant?

The grant covers 119,170 stock options with an exercise price of $0.67 per share and an expiration date of March 30, 2036. These options relate to PharmaCyte Biotech Common Stock and represent a compensation award rather than a cash purchase of existing shares.

When do Jonathan Schechter’s new PMCB stock options vest?

The options will vest in full on the date of PharmaCyte Biotech’s next annual meeting of stockholders. Vesting is conditioned on Mr. Schechter’s continued service with the company through that meeting, aligning the award with his ongoing board responsibilities.

How many PMCB stock options does Jonathan Schechter hold after this grant?

Following this transaction, Jonathan Schechter holds 119,170 stock options in PharmaCyte Biotech. This entire amount comes from the newly granted award reported in the Form 4, reflecting his current derivative position from this specific grant alone.

Is Jonathan Schechter’s PMCB Form 4 transaction a stock purchase or compensation award?

The Form 4 reports a compensation-related award, not an open-market stock purchase. The transaction code is A, described as a grant, award, or other acquisition, indicating stock options were granted to Mr. Schechter as part of his role, with no cash purchase involved.